MNKD - MannKind Corp - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

MNKD is currently covered by 4 analysts with an average price target of $5.54. This is a potential upside of $1.83 (49.33%) from yesterday's end of day stock price of $3.71.

MannKind Corp's activity chart (see below) currently has 38 price targets and 48 ratings on display. The stock rating distribution of MNKD is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 67.42% with an average time for these price targets to be met of 603.33 days.

Highest price target for MNKD is $12, Lowest price target is $12, average price target is $9.17.

Most recent stock forecast was given by STEVEN LICHTMAN from OPPENHEIMER on 28-Aug-2024. First documented stock forecast 06-Sep-2013.

Currently out of the existing stock ratings of MNKD, 9 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$12

$8.29 (223.45%)

$6.5

9 months 17 days ago
(28-Aug-2024)

2/3 (66.67%)

$6.1 (103.39%)

384

Buy

$8

$4.29 (115.63%)

$7.5

1 years 1 days ago
(13-Jun-2024)

2/4 (50%)

$2.96 (58.73%)

848

Buy

$7.5

$3.79 (102.16%)

$7.5

1 years 5 months 10 days ago
(04-Jan-2024)

9/11 (81.82%)

$3.68 (96.34%)

1182

Buy

$8

$3.87 (93.70%)

$4

4 years 3 months 22 days ago
(24-Feb-2021)

3/4 (75%)

$1.75 (92.09%)

297

Sell

7 years 3 months 17 days ago
(28-Feb-2018)

1/1 (100%)

$1.97 (39.17%)

2581

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is MNKD (MannKind Corp) average time for price targets to be met?

On average it took 603.33 days on average for the stock forecasts to be realized with a an average price target met ratio 67.42

Which analyst has the current highest performing score on MNKD (MannKind Corp) with a proven track record?

JOSH SCHIMMER

Which analyst has the current lower performing score on MNKD (MannKind Corp) with a proven track record?

STEVE BYRNE

Which analyst has the most public recommendations on MNKD (MannKind Corp)?

Josh Schimmer works at EVERCORE and has 3 price targets and 2 ratings on MNKD

Which analyst is the currently most bullish on MNKD (MannKind Corp)?

Shaunak Deepak with highest potential upside - $41.29

Which analyst is the currently most reserved on MNKD (MannKind Corp)?

Joshua Schimmer with lowest potential downside - -$0

MannKind Corp in the News

MannKind Corporation (MNKD): Among the Best Cancer Stocks to Invest in for Long-Term Gain

We recently published a list of 10 Best Cancer Stocks to Invest in for Long-Term Gains. In this article, we are going to take a look at where MannKind Corporation (NASDAQ:MNKD) stands against other best cancer stocks to invest in for long-term gain. Surging Cancer Cases and Costs Drive Growth in the Global Oncology Market...

MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates

MannKind (MNKD) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.05 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 33.33%. A quarter ago, it was expected that this...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?